#Medtech #Stocks in the News: Electromedical Technologies (OTCQB: $EMED)
Produces $4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT
SCOTTSDALE, AZ, November 20, 2020 (Investorideas.com Newswire) – Breaking Medical
Technology stock news - Electromedical
Technologies, Inc. (OTCQB:
EMED )
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, including the FDA cleared WellnessPro+, designed to
relieve chronic, intractable and acute pains by using frequencies and
electro-modulation, is pleased to announce that
the company has completed the production of over 1,200 units of its FDA cleared
WellnessPro+ device, representing approximately $4.2 million of inventory to
meet demand.
Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11201Electromedical-Technologies-EMED.asp
The Company began production in
September and has fully paid for and completed its first phase of inventory
buildup in order to meet rising demand as we transition into 2021. We want to
make sure that we do not run out of inventory which occurred in the first
quarter of this year.
Matthew Wolfson, Founder and
CEO of EMED, commented, “Every day more doctors and patients are realizing the
importance of using methods that will have a positive effect in reducing pain
without having negative effects on the immune system, especially in today’s pandemic
environment. The reason for the increase in
demand is that more and more people are realizing that there are other powerful
treatment options such as bioelectronics, that does not include injections,
invasive procedures or opioids that have the possibility of harmful side
effects such as addiction and death.”
Commenting further, Mr. Wolfson said, “This
inventory increase fits perfectly with our strategic plan of engaging and
onboarding hundreds of new medical practitioners and distributors. In today’s
economic environment, many people are seeking to create new revenue streams for
their families. We have a way to help thousands of people to live a better
quality of life, pain free and addiction free and at the same time provide a
real income opportunity for anyone who wishes to join our brand ambassador
team.” (https://electromedtech.com/register/)
Finally commenting, Mr. Wolfson
said, “In the world we live in today, people cannot afford the risks associated
with opioid-based drugs, but they need results. Word of mouth has been a very
valuable marketing tool because our device delivers a powerful solution to
chronic pain without any dangerous or harmful side effects. The Wellness Pro
produces real results so people can live pain free and get their lives back!”
About Electromedical Technologies
Headquartered in Scottsdale
Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially focused on the
treatment of various chronic, acute, intractable, and post-operative pain
conditions. Through university collaboration agreements the company is working
to develop a comprehensive research program in defining the effects of
electro-modulation on the human body by studying the impacts of electrical
fields in cell signaling and effects on virus assembly and immune responses
with the goal of improving human wellbeing. The company’s current cleared
product indications are for chronic acute post traumatic and post-operative,
intractable pain relief.
Our animal studies do not involve
any human testing, and are not related to our current products. We are
conducting this research to augment and advance the science of
electro-modulation in healthcare. The
United States Food and Drug Administration has not reviewed or approved our
animal research studies
For more information, visit www.electromedtech.com.
Safe Harbor Statement
This release contains
forward-looking statements that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although we believe
that the expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give no assurance
or guarantee that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should,"
"could," "expect," "anticipate,"
"estimate," "believe," "intend," or
"project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements are subject
to numerous factors and uncertainties, including but not limited to: adverse
economic conditions, competition, adverse federal, state and local government regulation,
international governmental regulation, inadequate capital, inability to carry
out research, development and commercialization plans, loss or retirement of
key executives and other specific risks. To the extent that statements in this
press release are not strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this release are subject to certain
risks and uncertainties that could cause actual results to differ materially
from the statements made.
Corporate Contact:
Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email: ceo@electromedtech.com
https://electromedtech.com
Paid News
-Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. Disclosure : this news release featuring Electromedical
Technologies, Inc.
(OTCQB: EMED) is a paid for news release on
Investorideas.com More disclaimer
info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Please read Investorideas.com
privacy policy: https://www.investorideas.com/About/Private_Policy.asp
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news
alerts at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
No comments:
Post a Comment